Conference Coverage
Conference Coverage
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection...
Conference Coverage
Eyes on ESC ‘21: Hope for EMPEROR-Preserved, guidelines remade
But the congress will feature far more than, potentially, results the heart failure world has been longing to see and a raft of new guidelines....
Conference Coverage
DOACs best aspirin after ventricular ablation: STROKE-VT
Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved....
Conference Coverage
ESC heart failure guideline to integrate bounty of new meds
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds...
Conference Coverage
Expert proposes rethinking the classification of SJS/TEN
“After leaving the hospital, people with SJS or people with TEN need to have ongoing care, consultation, and explanation so they and their...
Conference Coverage
ADA/EASD draft guidance aims to bring adults with type 1 diabetes out of shadows
The new draft ADA/EASD consensus report offers an algorithm for diagnosing type 1 diabetes, a clear call for state-of-the-art technology, and an...
Conference Coverage
EAS lipid guidance: Start high-risk patients on combo drug
Instead of starting very-high-risk patients unlikely to reach goal on a statin alone, clinicians should immediately reach for combination statin-...
Conference Coverage
Nocturnal hypoglycemia halved with insulin degludec vs. glargine
Researchers pitted degludec against glargine U100 in the toughest patients with type 1 diabetes, those who had severe nocturnal hypoglycemia.
Conference Coverage
SUSTAIN FORTE: Higher-dose semaglutide safely boosts glycemic control, weight loss
For patients with type 2 diabetes, doubling the weekly semaglutide dose modestly improved glycemic control and weight loss while maintaining...
Conference Coverage
‘Stunning’ twincretin beats semaglutide for A1c, weight reduction in T2D
Head-to-head pivotal trial results show weekly tirzepatide injections surpassed 1 mg semaglutide weekly for A1c reduction and weight loss.
Conference Coverage
Unmanaged diabetes, high blood glucose tied to COVID-19 severity
Findings suggest in part that hospitalized COVID-19 patients need aggressive treatment of hyperglycemia, regardless of the diagnosis of diabetes...